Quick Answer
Kiniksa Pharmaceuticals International, plc reported Revenue From Contract With Customer Excluding Assessed Tax of $677.56 million for the year ending 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +60.1% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Kiniksa Pharmaceuticals International, plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Kiniksa Pharmaceuticals International, plc's Revenue From Contract With Customer Excluding Assessed Tax has grown by 1,657.9%.
- Historical annual values: Fiscal year 2025: $677.56 million | Fiscal year 2024: $423.24 million | Fiscal year 2023: $270.26 million | Fiscal year 2022: $220.18 million | Fiscal year 2021: $38.54 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: